Effects of Low Concentration Hydrogen Inhalation on Asthma and Sleep Function in Mice

ZHAO Yue, WEI Lu, ZHANG Xue-wei, ZHU Li, DU Jun-rong

Abstract

This study was designed to investigate the effects of low concentration hydrogen inhalation on asthma and sleep function in mice and the potential mechanism.  Methods  In the asthma experiment, BALB/c mice were randomly divided into normal control group, asthma model group and hydrogen treatment group. After establishing ovalbumin (OVA)-induced asthma model, the hydrogen treatment group mice were treated by inhalation of hydrogen (24-26 mL/L per day) for 7 consecutive days, and the normal control group and asthma model group mice received similar treatment by inhalation of air. The levels of interleukin (IL)-4, IL-13, and interferon-γ (IFN-γ) in bronchoalveolar lavage fluid (BALF) were measured by commercially available ELISA kits. The levels of malondialdehyde (MDA) and glutathione (GSH), as well as the activity of superoxide dismutase (SOD) in lung tissue were detected by colorimetric assays. The pathological changes in lung tissue were assessed by HE staining. In the sleep experiment, ICR mice were randomly divided into blank control group and 1 d, 3 d, 5 d hydrogen treatment groups and diazepam group. The effects of inhalation of 24-26 mL/L per day hydrogen on the sleep duration induced by intraperitoneal injection of upper-threshold dose of sodium pentobarbital and the sleep latency in response to subthreshold dose were evaluated.  Results  In the asthma experiment, the asthma model group showed higher levels of IL-4 and IL-13 (P<0.05) and lower levels of IFN-γ (P<0.001) in BALF, as compared to the normal control group. The content of MDA in lung tissue was also significantly increased (P<0.01), companied by a decreased GSH concentration (P <0.05) and a mildly reduced SOD activity (P>0.05). Compared to the asthma model group, treatment with hydrogen significantly decreased the levels of IL-4 and IL-13 and increased the level of IFN-γ in BALF (P<0.05). Moreover, without alteration of the MDA production (P>0.05), hydrogen inhalation greatly increased GSH level and restored the SOD activity (P<0.05) in lung tissue. Additionally, the HE staining data showed that the hydrogen treatment attenuated the pulmonary histopathological changes. In the sleep experiment, compared with the blank control group, the sleep latency was significantly shorter (P<0.05) and the sleep duration was longer (P<0.001) in all the hydrogen treatment groups after receiving an upper-threshold dose of sodium pentobarbital. Meanwhile, in all the hydrogen treatment groups, the sleep latency was significantly longer (P<0.001) and the sleep duration was shorter (P<0.001) when compared to the diazepam group. Compared with the blank control group, after intraperitoneal injection of a subthreshold dose of sodium pentobarbital, the sleep latency was significantly increased in both 1 d and 5 d hydrogen treatment groups, and there was no significant difference as compared to the diazepam group. In the 3 d hydrogen treatment group, the sleep latency was only slightly increased (P>0.05), which was significantly lower than that of the diazepam group (P<0.05).  Conclusion  Low concentration hydrogen inhalation could alleviate OVA-induced asthma in mice, and the mechanism might be related to the anti-oxidative and anti-inflammatory effects of hydrogen. Also, low concentration hydrogen inhalation could improve sleep function in mice.

 

Keywords: Low concentration hydrogen, Asthma, Sleep function

 

Full Text:

PDF


References


MISHRA V， BANGA J， SILVEYRA P. Oxidative stress and cellular pathways of asthma and inflammation: therapeutic strategies and pharmacological targets. Pharmacol Ther，2018，181: 169–182.

OPINA M T， MOORE W C. Phenotype-driven therapeutics in severe asthma. Curr Allergy Asthma Rep， 2017， 17(2): 10[2019-08-14]. https://link.springer.com/article/10.1007%2Fs11882-017-0678-1. doi: 10.1007/s11882-017-0678-1.

IIDA A， NOSAKA N， YUMOTO T， et al. The clinical application of hydrogen as a medical treatment. Acta Med Okayama，2016，70(5): 331–337.

HUANG P， WEI S， HUANG W， et al. Hydrogen gas inhalation enhances alveolar macrophage phagocytosis in an ovalbumin-induced asthma model. Int Immunopharmacol， 2019， 74: 105646[2019-04-18]. https://doi.org/10.1016/j.intimp.2019.05.031.

KAVANAGH J， JACKSON D J， KENT B D. Sleep and asthma. Curr Opin Pulm Med，2018，24(6): 569–573.

TAYLOR D J， PETERSON A L， PRUIKSMA K E， et al. Impact of cognitive behavioral therapy for insomnia disorder on sleep and comorbid symptoms in military personnel: a randomized clinical trial. Sleep， 2018， 41(6) [2019-08-14]. https://doi.org/10.1093/sleep/zsy069.

MATSUMOTO A， YAMAFUJI M， TACHIBANA T， et al. 'Oralhydrogen water' induces neuroprotective ghrelin secretion in mice. Sci Rep， 2013， 3: 3273[2019-08-14]. https://www.nature.com/articles/srep03273. doi: 10.1038/srep03273.

MIZUNO K， SASAKI A T， EBISU K， et al. Hydrogen-rich water for improvements of mood, anxiety, and autonomic nerve function in daily life. Med Gas Res，2017，7(4): 247–255.

LECKER B， ILLI L， LEMMER A， et al. Biological hydrogen methanation—a review. Bioresour Technol，2017，245(Pt A): 1220–1228. MATEI N， CAMARA R， ZHANG J H. Emerging mechanisms and novel applications of hydrogen gas therapy. Med Gas Res，2018，8(3): 98–102. LI S，

LIAO R， SHENG X， et al. Hydrogen gas in cancer treatment. Front Oncol， 2019， 9: 696[2019-08-14]. https://doi.org/10.3389/fonc.2019. 00696.

HUANG C S， KAWAMURA T， TOYODA Y， et al. Recent advances in hydrogen research as a therapeutic medical gas. Free Radic Res，2010， 44(9): 971–982.

CHEN X， LI X， GU W， et al. LAT alleviates Th2/Treg imbalance in an OVA-induced allergic asthma mouse model through LAT-PLC-γ1 interaction. Int Immunopharmacol，2017，44: 9–15.

ROBINSON M J， PROUT M， MEARNS H， et al. IL-4 haploinsufficiency specifically impairs IgE responses against allergens in mice. J Immunol， 2017，198(5): 1815–1822.

RAPHAEL I， NALAWADE S， EAGAR T N， et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine，2015，74(1): 5–17.

SAHINER U M， BIRBEN E， ERZURUM S， et al. Oxidative stress in asthma: part of the puzzle. Pediatr Allergy Immunol，2018，29(8): 789–800.

COMHAIR S A， ERZURUM S C. Redox control of asthma: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal，2010， 12(1): 93–124.

BEN A A， BEN N H， FETOUI H， et al. Alteration in systemic markers of oxidative and antioxidative status in Tunisian patients with asthma: relationships with clinical severity and airflow limitation. J Asthma，2016， 53(3): 227–237.

FERINI S L， GALBIATI A， COMBI R. Sleep disorder-related headaches. Neurol Sci，2019，40(Suppl 1): 107–113.


Refbacks

  • There are currently no refbacks.